Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Targimmune Therapeutics AG has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners across 2 art units, combining examiner-level dispersion with some shared art-unit context.
FAY, ZOHREH ALEMZADEH is the busiest examiner, with 1 pending action. A coordinated review can preserve consistent biotechnology claim language, while each response should address its own examiner and examination record.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316828 | CASTRATION RESISTANT PROSTATE CANCER | LIPPOLIS, ALEXANDRA ROSE | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316828 | CASTRATION RESISTANT PROSTATE CANCER | LIPPOLIS, ALEXANDRA ROSE | 31d overdue |
| 17594054 | IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | POLIAKOVA-GEORGAN, EKATERINA | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706231 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | FAY, ZOHREH ALEMZADEH | 1617 | §112Other | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18316828 | CASTRATION RESISTANT PROSTATE CANCER | LIPPOLIS, ALEXANDRA ROSE | 1637 | §101§103 | Final Rejection | 31d overdue | Pending | May 12, 2023 |
| 17594054 | IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103§112DP | Non-Final OA | — | Pending | Sep 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTargimmune Therapeutics AG has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Zohreh Alemzadeh Fay has the most, with 1 of Targimmune Therapeutics AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
